MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis
Hamed Alborzinia,Andrés F. Flórez,Sina Kreth,Lena M. Brückner,Umut Yildiz,Moritz Gartlgruber,Dorett I. Odoni,Gernot Poschet,Karolina Garbowicz,Chunxuan Shao,Corinna Klein,Jasmin Meier,Petra Zeisberger,Michal Nadler-Holly,Matthias Ziehm,Franziska Paul,Jürgen Burhenne,Emma Bell,Marjan Shaikhkarami,Roberto Würth,Sabine A. Stainczyk,Elisa M. Wecht,Jochen Kreth,Michael Büttner,Naveed Ishaque,Matthias Schlesner,Barbara Nicke,Carlo Stresemann,María Llamazares-Prada,Jan H. Reiling,Matthias Fischer,Ido Amit,Matthias Selbach,Carl Herrmann,Stefan Wölfl,Kai-Oliver Henrich,Thomas Höfer,Andreas Trumpp,Frank Westermann
DOI: https://doi.org/10.1038/s43018-022-00355-4
IF: 22.7
2022-04-29
Nature Cancer
Abstract:Nature Cancer, Published online: 28 April 2022; doi:10.1038/s43018-022-00355-4 Alborzinia et al. report that MYCN-amplified neuroblastoma undergoes ferroptosis in the absence of intracellular cysteine, suggesting a combination of cysteine depletion and concomitant GPX4 inactivation as a potential therapeutic approach.
What problem does this paper attempt to address?